Grufity logo
Grufity logo
TENX

TENX - Tenax Therapeutics Inc Stock Price, Fair Value and News

$11.31-0.24 (-2.08%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

30/100

TENX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

30/100

TENX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TENX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TENX Price Action

Last 7 days

9.4%

Last 30 days

-3.8%

Last 90 days

-24.0%

Trailing 12 Months

102.3%

TENX RSI Chart

TENX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TENX Valuation

Market Cap

280.4M

Price/Earnings (Trailing)

-4.84

Price/Sales (Trailing)

74.77

Price/Free Cashflow

-7.36

TENX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TENX Fundamentals

TENX Revenue

Revenue (TTM)

3.8M

TENX Earnings

Earnings (TTM)

-57.9M

Earnings Growth (Yr)

-51%

Earnings Growth (Qtr)

-1.13%

TENX Profitability

Return on Equity

-50.49%

Return on Assets

-47.01%

Free Cashflow Yield

-13.59%

TENX Investor Care

Shares Dilution (1Y)

511.41%

Diluted EPS (TTM)

-1.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20263.8M---
20252.7M3.6M3.9M3.8M
2024525.7K489.9K1.0M1.9M
2023-267.2K339.9K407.7K
2015-49.3K194.6K-
2014444.9K158.9K--
20131.1M1.2M1.1M625.5K
2012311.7K363.8K611.0K1.0M
2011-104.1K122.0K190.1K
2010----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Tenax Therapeutics Inc

TENX
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
 CEO
 WEBSITEtenaxthera.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Tenax Therapeutics Inc Frequently Asked Questions

TENX is the stock ticker symbol of Tenax Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Tenax Therapeutics Inc is 280.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, TENX's PE ratio (Price to Earnings) is -4.84 and Price to Sales (PS) ratio is 74.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TENX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Tenax Therapeutics Inc has provided -0.59 (multiply by 100 for percentage) rate of return.